What are the payment terms?

We accept LC, T/T, D/P, PayPal, Western Union, and small-amount payments.

Is this product for human use?

No, it is for veterinary use only and not for hens producing eggs for human consumption.

5%+10% Spectinomycin and Lincomycin Veterinary Injection (GMP Factory-Made)

Name: 5%+10% Spectinomycin and Lincomycin Veterinary Injection (GMP Factory-Made)
Brand: Henan Muxiang Biological Co., Ltd.
SKU: 2227009395

Henan, ChinaHenan Muxiang Biological Co., Ltd.

US$1.68

1,000 Pieces

Sample price:US$5.00/piece.Request sample

Product profile

Customization

Available

Varieties

General Disease Prevention Medicine

Component

Chemical Synthetic Drugs

Model NO.

Liquid

Type

The First Class

Pharmacodynamic Influential Factors

Combined Medication

Storage Method

Light Proof

Transport Package

Carton

Specification

100ml/bottle/box

Trademark

Moosun

Origin

China

HS Code

3004909090

Production Capacity

50000pieces/Month

Key features

Broad-Spectrum Efficacy: Treats GI and respiratory infections caused by sensitive micro-organisms in various animals.

Multi-Species Application: Effective for cattle, cats, dogs, goats, poultry, sheep, swine, and turkeys.

GMP Factory Standard: Manufactured in a GMP-certified facility ensuring high quality and safety standards.

Precise Dosage Guidelines: Clear administration instructions for intramuscular or subcutaneous use per animal weight.

OEM/ODM Support: Customized packaging and branding services available for international clients.

Established Manufacturer: Trusted producer with over 18 years of experience and 360 employees.

Global Market Reach: Exports to North America, Europe, Southeast Asia, Africa, and other major regions.

Flexible Payment Terms: Accepts LC, T/T, D/P, PayPal, Western Union, and small-amount payments.

Company profile

Henan Muxiang Biological Co., Ltd.

Henan, China

CertifiedBusiness Type: Manufacturer/Factory & Trading Company CertifiedR&D Capacity: ODM Service Available & OEM Service AvailableExport Year: 2016-02-01 CertifiedNearest Port: Shanghai Port, Qingdao PortAverage Response Time: ≤10.82h CertifiedTerms of Payment: LC, T/T, D/P, etc.

AI-Powered supplier vetting

SummaryHenan Muxiang Biological Co., Ltd. is a China-based limited-company factory established in 2004, with 360 employees and operations in veterinary pharmaceuticals and animal-health products. The supplier reports seven pharmaceutical production lines, eight vaccine production lines, first-class production and inspection equipment, GMP management, ISO9001:2015 certification, and ISO/CNAS laboratory certification. Its R&D resources include more than 40 core personnel, over 30 of whom hold doctoral or master's degrees, while 21–30 quality-control staff are reported. The company exports to multiple global regions, has self-operated import and export rights, and states a one-month order-fulfillment period in both peak and off-peak seasons. Evidence supports capabilities in certification, innovation, production, and international operations. However, the provided information does not sufficiently establish after-sales service performance, financial credibility, customization execution, or specific customer cases.

Supplier typeThe supplier is identified as a limited company and a factory in the manufacturing industry, with its operating location in Henan, China. This indicates a direct manufacturing entity rather than only a trading or intermediary business.

CertificationsThe supplier reports a systematic GMP management system, ISO/CNAS laboratory international certification, and an ISO9001:2015 certificate. These stated certifications and quality systems provide explicit evidence of formal quality-management capability.

R&D capabilityThe supplier reports more than 40 core R&D personnel, including over 30 doctors or master's degree graduates, 20 years of preparation-technology experience among R&D engineers, and advanced R&D platforms such as a National Enterprise Technology Center, National Postdoctoral Research Station, and Academician Workstation. It also reports improving herbal active-ingredient extraction by more than 30% versus a traditional process, supporting a strong stated innovation profile.

Production capacityThe supplier reports seven pharmaceutical production lines and eight vaccine production lines, first-class production and inspection equipment, six production lines in a separate operational data field, and one-month order fulfillment in both peak and off-peak seasons. Although the line-count figures are not fully consistent across the slices, the evidence clearly supports substantial pharmaceutical and vaccine manufacturing capability.